{"protocolSection":{"identificationModule":{"nctId":"NCT05194540","orgStudyIdInfo":{"id":"LP0162-1338"},"secondaryIdInfos":[{"id":"U1111-1283-2072","type":"OTHER","domain":"World Health Organization (WHO)"}],"organization":{"fullName":"LEO Pharma","class":"INDUSTRY"},"briefTitle":"Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Adults and Adolescents With Moderate to Severe Atopic Dermatitis (INJECZTRA)","officialTitle":"An Open-label, Single-arm, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Subjects With Moderate-to-severe Atopic Dermatitis","acronym":"INJECZTRA"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-01-13","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2023-06-06","type":"ACTUAL"},"completionDateStruct":{"date":"2023-06-21","type":"ACTUAL"},"studyFirstSubmitDate":"2022-01-04","studyFirstSubmitQcDate":"2022-01-04","studyFirstPostDateStruct":{"date":"2022-01-18","type":"ACTUAL"},"resultsFirstSubmitDate":"2024-05-06","resultsFirstSubmitQcDate":"2024-06-17","resultsFirstPostDateStruct":{"date":"2024-06-20","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-02-21","lastUpdatePostDateStruct":{"date":"2025-03-11","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"LEO Pharma","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this trial is to evaluate the efficacy and safety of tralokinumab administered as subcutaneous (SC) injection by an autoinjector in adults and adolescents (age 12 to 17 years) with moderate-to-severe atopic dermatitis (AD).","detailedDescription":"This is a single-arm, phase 3 trial designed to evaluate the efficacy and safety of tralokinumab when administered by an autoinjector in adults and adolescent subjects with moderate-to-severe AD. At baseline, the subjects will receive an initial SC dose of 600 mg tralokinumab. For the rest of the treatment period, all subjects will self-administer a dose of 300 mg tralokinumab every other week for 14 weeks."},"conditionsModule":{"conditions":["Atopic Dermatitis"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":136,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Tralokinumab subcutaneous dosing by an autoinjector","type":"EXPERIMENTAL","description":"An initial SC dose of 600 mg tralokinumab at baseline followed by self-administration of a 300 mg dose of tralokinumab every other week for 14 weeks.","interventionNames":["Drug: Tralokinumab"]}],"interventions":[{"type":"DRUG","name":"Tralokinumab","description":"Tralokinumab is a human recombinant monoclonal antibody of immunoglobulin G4 (IgG4) subclass that specifically binds to human interleukin-13 (IL-13) and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous administration","armGroupLabels":["Tralokinumab subcutaneous dosing by an autoinjector"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16","description":"IGA is an instrument used in clinical trials to rate the severity of the participant's global AD and is based on a 5-point scale ranging from 0 (clear) to 4 (severe)","timeFrame":"At Week 16"},{"measure":"At Least 75% Reduction in Eczema Area and Severity Index (EASI75) at Week 16","description":"Eczema Area and Severity Index (EASI) is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. EASI is a composite index with scores ranging from 0 to 72, where higher values indicate a more severe or more extensive condition","timeFrame":"At Week 16"}],"secondaryOutcomes":[{"measure":"Number of Treatment-emergent Adverse Events (AEs) From Baseline to Week 16","description":"An AE will be considered treatment emergent if it started after the first injection of trial drug","timeFrame":"From Week 0 to Week 16"},{"measure":"Presence of Treatment-emergent Anti-drug Antibodies (ADA) From Baseline to Week 16","description":"Serum samples for determination of presence or absence of ADA will be analysed using a validated bioanalytical method","timeFrame":"From Week 0 to Week 16"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age 12 years and above.\n* Subject able and willing to self-administer tralokinumab with Device A.\n* Diagnosis of AD as defined by the Hanifin and Rajka (1980) criteria for AD.\n* History of AD for ≥1 year.\n* A recent history (within 1 year before the screening visit) of inadequate response to treatment with topical medication or for whom topical treatments are otherwise medically inadvisable.\n* AD involvement of ≥10% body surface area at screening and baseline.\n* An EASI score of ≥12 at screening and ≥16 at baseline.\n* An IGA score of ≥3 at screening and at baseline.\n* Applied a stable dose of emollient twice daily (or more, as needed) for at least 14 days before baseline.\n\nExclusion Criteria:\n\n* Active dermatologic conditions that may confound the diagnosis of AD or would interfere with assessment of treatment.\n* Use of tanning beds or phototherapy within 4 weeks prior to baseline.\n* Treatment with systemic immunosuppressive/immunomodulating drugs and/or systemic corticosteroids within 4 weeks prior to baseline.\n* Treatment with topical corticosteroids, topical calcineurin inhibitors, topical phosphodiesterase 4 inhibitors, or topical Janus kinase inhibitors within 2 weeks prior to baseline.\n* Receipt of any marketed biological therapy (i.e. immunoglobulin, anti immunoglobulin E) including dupilumab or investigational biologic agents 3 to 6 months prior to baseline.\n* Active skin infections within 1 week prior to baseline.\n* Clinically significant infection within 4 weeks prior to baseline.\n* A helminth parasitic infection within 6 months prior to the date informed consent is obtained.\n* Tuberculosis requiring treatment within 12 months prior to screening.\n* Known primary immunodeficiency disorder.","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Expert","affiliation":"LEO Pharma","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"LEO Pharma Investigator","city":"Birmingham","state":"Alabama","zip":"35205","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"LEO Pharma Investigator","city":"Birmingham","state":"Alabama","zip":"35209","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"LEO Pharma Investigator","city":"Fort Smith","state":"Arkansas","zip":"72916","country":"United States","geoPoint":{"lat":35.38592,"lon":-94.39855}},{"facility":"LEO Pharma Investigator","city":"Fountain Valley","state":"California","zip":"92708","country":"United States","geoPoint":{"lat":33.70918,"lon":-117.95367}},{"facility":"LEO Pharma Investigator","city":"Fremont","state":"California","zip":"94538","country":"United States","geoPoint":{"lat":37.54827,"lon":-121.98857}},{"facility":"LEO Pharma Investigational Site","city":"Inglewood","state":"California","zip":"90301","country":"United States","geoPoint":{"lat":33.96168,"lon":-118.35313}},{"facility":"LEO Pharma Investigator","city":"Los Angeles","state":"California","zip":"90025","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"LEO Pharma Investigator","city":"San Diego","state":"California","zip":"92103","country":"United States","geoPoint":{"lat":32.71571,"lon":-117.16472}},{"facility":"LEO Pharma Investigator","city":"San Diego","state":"California","zip":"92130","country":"United States","geoPoint":{"lat":32.71571,"lon":-117.16472}},{"facility":"LEO Pharma Investigator","city":"Santa Ana","state":"California","zip":"92701","country":"United States","geoPoint":{"lat":33.74557,"lon":-117.86783}},{"facility":"LEO Pharma Investigator","city":"Centennial","state":"Colorado","zip":"80111","country":"United States","geoPoint":{"lat":39.57916,"lon":-104.87692}},{"facility":"LEO Pharma Investigator","city":"Farmington","state":"Connecticut","zip":"06032","country":"United States","geoPoint":{"lat":41.71982,"lon":-72.83204}},{"facility":"LEO Pharma Investigational Site","city":"Hialeah","state":"Florida","zip":"33012","country":"United States","geoPoint":{"lat":25.8576,"lon":-80.27811}},{"facility":"LEO Pharma Investigator","city":"Sanford","state":"Florida","zip":"32771","country":"United States","geoPoint":{"lat":28.80055,"lon":-81.27312}},{"facility":"LEO Pharma Investigator","city":"Libertyville","state":"Illinois","zip":"60048","country":"United States","geoPoint":{"lat":42.28308,"lon":-87.95313}},{"facility":"LEO Pharma Investigator","city":"Overland Park","state":"Kansas","zip":"66210","country":"United States","geoPoint":{"lat":38.98223,"lon":-94.67079}},{"facility":"LEO Pharma Investigator","city":"Bangor","state":"Maine","zip":"04401","country":"United States","geoPoint":{"lat":44.79884,"lon":-68.77265}},{"facility":"LEO Pharma Investigator","city":"Detroit","state":"Michigan","zip":"48202","country":"United States","geoPoint":{"lat":42.33143,"lon":-83.04575}},{"facility":"LEO Pharma Investigator","city":"Portsmouth","state":"New Hampshire","zip":"03801","country":"United States","geoPoint":{"lat":43.07704,"lon":-70.75766}},{"facility":"LEO Pharma Investigator","city":"Cortland","state":"New York","zip":"13045","country":"United States","geoPoint":{"lat":42.60118,"lon":-76.18048}},{"facility":"LEO Pharma Investigator","city":"Horseheads","state":"New York","zip":"14845","country":"United States","geoPoint":{"lat":42.16702,"lon":-76.82051}},{"facility":"LEO Pharma Investigator","city":"Bexley","state":"Ohio","zip":"43209","country":"United States","geoPoint":{"lat":39.96895,"lon":-82.93768}},{"facility":"LEO Pharma Investigator","city":"Toledo","state":"Ohio","zip":"43617","country":"United States","geoPoint":{"lat":41.66394,"lon":-83.55521}},{"facility":"LEO Pharma Investigator","city":"Tulsa","state":"Oklahoma","zip":"74136","country":"United States","geoPoint":{"lat":36.15398,"lon":-95.99277}},{"facility":"LEO Pharma Investigator","city":"Portland","state":"Oregon","zip":"97210","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"LEO Pharma Investigator","city":"Dallas","state":"Texas","zip":"75225","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"LEO Pharma Investigator","city":"Frisco","state":"Texas","zip":"75034","country":"United States","geoPoint":{"lat":33.15067,"lon":-96.82361}},{"facility":"LEO Pharma Investigator","city":"San Antonio","state":"Texas","zip":"78218","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"LEO Pharma Investigator","city":"Webster","state":"Texas","zip":"77598","country":"United States","geoPoint":{"lat":29.53773,"lon":-95.11826}}]},"referencesModule":{"references":[{"pmid":"40681936","type":"DERIVED","citation":"Soung J, Laquer V, Zirwas M, van Iperen P, Stinson JC, Albertsen KL, Stein Gold L. The Tralokinumab Pre-Filled Pen Improved Atopic Dermatitis Signs and Symptoms and Was Well Tolerated in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A 16-Week, Open-Label, Single-Arm Phase 3 Study (INJECZTRA). Dermatol Ther (Heidelb). 2025 Sep;15(9):2631-2644. doi: 10.1007/s13555-025-01490-3. Epub 2025 Jul 18."}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Tralokinumab Subcutaneous Dosing by an Autoinjector","description":"An initial SC dose of 600 mg tralokinumab at baseline followed by self-administration of a 300 mg dose of tralokinumab every other week for 14 weeks.\n\nTralokinumab: Tralokinumab is a human recombinant monoclonal antibody of immunoglobulin G4 (IgG4) subclass that specifically binds to human interleukin-13 (IL-13) and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous administration"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"136"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"117"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"19"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Tralokinumab Subcutaneous Dosing by an Autoinjector","description":"An initial SC dose of 600 mg tralokinumab at baseline followed by self-administration of a 300 mg dose of tralokinumab every other week for 14 weeks.\n\nTralokinumab: Tralokinumab is a human recombinant monoclonal antibody of immunoglobulin G4 (IgG4) subclass that specifically binds to human interleukin-13 (IL-13) and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous administration"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"136"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"36.4","spread":"20.2"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"72"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"64"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"32"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"103"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"1"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"2"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"14"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"1"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"32"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"81"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"5"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"1"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"136"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16","description":"IGA is an instrument used in clinical trials to rate the severity of the participant's global AD and is based on a 5-point scale ranging from 0 (clear) to 4 (severe)","populationDescription":"FAS, full analysis set","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of subjects","timeFrame":"At Week 16","groups":[{"id":"OG000","title":"Tralokinumab Subcutaneous Dosing by an Autoinjector","description":"An initial SC dose of 600 mg tralokinumab at baseline followed by self-administration of a 300 mg dose of tralokinumab every other week for 14 weeks.\n\nTralokinumab: Tralokinumab is a human recombinant monoclonal antibody of immunoglobulin G4 (IgG4) subclass that specifically binds to human interleukin-13 (IL-13) and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous administration"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"136"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.7","lowerLimit":"21.7","upperLimit":"36.8"}]}]}]},{"type":"PRIMARY","title":"At Least 75% Reduction in Eczema Area and Severity Index (EASI75) at Week 16","description":"Eczema Area and Severity Index (EASI) is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. EASI is a composite index with scores ranging from 0 to 72, where higher values indicate a more severe or more extensive condition","populationDescription":"FAS, full analysis set","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of subjects","timeFrame":"At Week 16","groups":[{"id":"OG000","title":"Tralokinumab Subcutaneous Dosing by an Autoinjector","description":"An initial SC dose of 600 mg tralokinumab at baseline followed by self-administration of a 300 mg dose of tralokinumab every other week for 14 weeks.\n\nTralokinumab: Tralokinumab is a human recombinant monoclonal antibody of immunoglobulin G4 (IgG4) subclass that specifically binds to human interleukin-13 (IL-13) and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous administration"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"136"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.4","lowerLimit":"35.3","upperLimit":"51.8"}]}]}]},{"type":"SECONDARY","title":"Number of Treatment-emergent Adverse Events (AEs) From Baseline to Week 16","description":"An AE will be considered treatment emergent if it started after the first injection of trial drug","populationDescription":"SAF, safety analysis set","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"events","timeFrame":"From Week 0 to Week 16","groups":[{"id":"OG000","title":"Tralokinumab Subcutaneous Dosing by an Autoinjector","description":"An initial SC dose of 600 mg tralokinumab at baseline followed by self-administration of a 300 mg dose of tralokinumab every other week for 14 weeks.\n\nTralokinumab: Tralokinumab is a human recombinant monoclonal antibody of immunoglobulin G4 (IgG4) subclass that specifically binds to human interleukin-13 (IL-13) and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous administration"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"136"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86"}]}]}]},{"type":"SECONDARY","title":"Presence of Treatment-emergent Anti-drug Antibodies (ADA) From Baseline to Week 16","description":"Serum samples for determination of presence or absence of ADA will be analysed using a validated bioanalytical method","populationDescription":"SAF, safety analysis set","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"From Week 0 to Week 16","groups":[{"id":"OG000","title":"Tralokinumab Subcutaneous Dosing by an Autoinjector","description":"An initial SC dose of 600 mg tralokinumab at baseline followed by self-administration of a 300 mg dose of tralokinumab every other week for 14 weeks.\n\nTralokinumab: Tralokinumab is a human recombinant monoclonal antibody of immunoglobulin G4 (IgG4) subclass that specifically binds to human interleukin-13 (IL-13) and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous administration"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"136"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"2","timeFrame":"Initial Treatment Period: Week 0 to week 16, Safety Follow- Up Period: Week 16 to Week 20.","eventGroups":[{"id":"EG000","title":"Tralokinumab+TCS Initial Treatment Period Week 0 to Week 16","description":"Tralokinumab+TCS (N=136)","deathsNumAffected":0,"deathsNumAtRisk":136,"seriousNumAffected":0,"seriousNumAtRisk":136,"otherNumAffected":24,"otherNumAtRisk":136},{"id":"EG001","title":"Safety Follow-Up Week 16 to Week 20","description":"Safety Follow-Up (N=131)","deathsNumAffected":0,"deathsNumAtRisk":131,"seriousNumAffected":0,"seriousNumAtRisk":131,"otherNumAffected":0,"otherNumAtRisk":131}],"otherEvents":[{"term":"Injection site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":136},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":131}]},{"term":"Injection site reaction","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":8,"numAtRisk":136},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":131}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":136},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":131}]},{"term":"Conjunctivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":136},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":131}]},{"term":"Dermatitis infected","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":136},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":131}]},{"term":"Dermatitis atopic","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":136},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":131}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The sponsor seeks publication of all clinical trials in peer-reviewed journals within 12 months after completion or termination of the clinical trial, regardless of whether the findings are positive or negative. If no publication is submitted by the sponsor within these 12 months, the investigator has the right to publish the results from clinical trial generated by him/herself."},"pointOfContact":{"title":"Clinical Disclosure","organization":"Leo Pharma","email":"disclosure@leo-pharma.com","phone":"+45 44945888"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2022-08-24","uploadDate":"2024-04-15T05:48","filename":"Prot_000.pdf","size":1073348},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2023-04-26","uploadDate":"2024-04-15T05:49","filename":"SAP_001.pdf","size":508241}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-12","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2024-06-04","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D003876","term":"Dermatitis, Atopic"}],"ancestors":[{"id":"D012873","term":"Skin Diseases, Genetic"},{"id":"D030342","term":"Genetic Diseases, Inborn"},{"id":"D009358","term":"Congenital, Hereditary, and Neonatal Diseases and Abnormalities"},{"id":"D003872","term":"Dermatitis"},{"id":"D012871","term":"Skin Diseases"},{"id":"D017437","term":"Skin and Connective Tissue Diseases"},{"id":"D017443","term":"Skin Diseases, Eczematous"},{"id":"D006969","term":"Hypersensitivity, Immediate"},{"id":"D006967","term":"Hypersensitivity"},{"id":"D007154","term":"Immune System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C574065","term":"tralokinumab"}]}},"hasResults":true}
